NCT01730469View on ClinicalTrials.gov

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Fabry Disease
Interventions
DRUG

AT1001 150 mg

AT1001 150mg is available as a capsule

Trial Locations (4)

32809

GSK Investigational Site, Orlando

33014

GSK Investigational Site, Miami

33169

GSK Investigational Site, Miami

92626

GSK Investigational Site, Costa Mesa

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY